Profile data is unavailable for this security.
About the company
Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.
- Revenue in DKK (TTM)259.83m
- Net income in DKK-957.00m
- Incorporated1997
- Employees345.00
- LocationZealand Pharma A/SSydmarken 11SOEBORG 2860DenmarkDNK
- Phone+45 88773600
- Fax+45 88773898
- Websitehttps://www.zealandpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calliditas Therapeutics AB | 194.15m | -404.81m | 3.53bn | 71.00 | -- | 5.92 | -- | 18.19 | -11.38 | -11.38 | 5.47 | 16.38 | 0.2077 | 1.08 | 88.21 | 4,228,500.00 | -43.88 | -31.46 | -49.82 | -34.68 | 17.60 | -- | -211.31 | -288.51 | 5.36 | -88.31 | 0.1976 | -- | 26,141.08 | -- | -15.41 | -- | 145.12 | -- |
| Pharming Group N.V. | 1.40bn | 112.79m | 3.58bn | 321.00 | 34.35 | 2.63 | 14.27 | 2.56 | 0.0216 | 0.0216 | 0.2614 | 0.2818 | 0.4876 | 0.8724 | 6.04 | 587,016.40 | 3.92 | 2.73 | 4.62 | 3.87 | 89.37 | 87.36 | 8.04 | 4.39 | 4.75 | -- | 0.4561 | -- | -6.27 | 62.49 | -57.62 | -- | 66.17 | -- |
| Basilea Pharmaceutica AG | 1.09bn | -50.27m | 3.59bn | 154.00 | -- | -- | -- | 3.30 | -0.613 | -0.613 | 12.68 | -4.95 | 0.621 | 1.09 | 2.86 | 961,831.20 | -2.86 | -6.90 | -5.41 | -9.70 | 83.75 | 85.05 | -4.61 | -14.70 | 1.25 | 0.145 | 1.37 | -- | 16.06 | 17.55 | 53.60 | -- | 14.82 | -- |
| Selcuk Ecza Deposu Ticaret ve Sanayi AS | 12.10bn | 495.89m | 3.88bn | 6.60k | 7.83 | 1.90 | 7.31 | 0.3206 | 1.91 | 1.91 | 46.69 | 7.89 | 2.33 | 9.01 | 6.33 | 4,410,280.00 | 9.53 | 7.50 | 26.05 | 19.39 | 9.17 | 7.89 | 4.10 | 3.25 | 1.08 | -- | 0.035 | 22.30 | 24.67 | 24.85 | 57.25 | 30.52 | 10.13 | 43.21 |
| Oxford BioMedica plc | 1.23bn | 164.37m | 4.00bn | 815.00 | 21.43 | 2.21 | 14.69 | 3.24 | 0.2245 | 0.2245 | 1.67 | 2.17 | 0.6781 | 7.32 | 3.58 | 175,211.00 | 9.03 | -0.756 | 11.34 | -0.9976 | 57.87 | 55.20 | 13.31 | -1.20 | 4.63 | 20.40 | 0.0475 | -- | 62.77 | 38.74 | 404.42 | -- | 7.94 | -- |
| Puretech Health PLC | 122.61m | -427.01m | 4.11bn | 95.00 | -- | 0.9845 | -- | 33.51 | -0.1728 | -0.1728 | 0.0495 | 1.68 | 0.018 | -- | 6.07 | 149,267.80 | -6.48 | 4.86 | -8.07 | 6.24 | -- | -- | -360.65 | 260.53 | -- | -- | 0.0818 | 0.00 | 47.76 | 31.45 | -1,111.83 | -- | 9.02 | -- |
| Ergomed PLC | 1.03bn | 109.58m | 4.25bn | 1.26k | 39.40 | 7.23 | 27.72 | 4.14 | 0.2505 | 0.2505 | 2.34 | 1.36 | 1.20 | -- | 5.06 | 94,486.85 | 12.78 | 4.27 | 19.60 | 6.13 | 40.78 | 41.18 | 10.69 | 3.85 | -- | 53.75 | 0.0383 | 0.00 | 37.26 | 24.76 | 30.90 | -- | -2.38 | -- |
| Pharmanutra SpA | 541.15m | 109.75m | 4.41bn | 64.00 | 40.19 | 12.64 | 38.53 | 8.15 | 1.52 | 1.52 | 7.51 | 4.84 | 1.11 | 0.8189 | 4.13 | 1,172,839.00 | 22.60 | 23.06 | 29.73 | 32.33 | 97.04 | 95.39 | 20.28 | 19.37 | 2.93 | -- | 0.113 | 50.80 | 20.66 | 15.75 | -2.14 | 29.03 | 18.07 | -- |
| Northern Data AG | 121.88m | -627.05m | 4.52bn | 157.00 | -- | 2.11 | -- | 37.05 | -7.25 | -7.25 | 1.41 | 12.06 | -- | -- | -- | 104,314.40 | -- | -35.75 | -- | -72.57 | 37.20 | -6.61 | -514.48 | -343.85 | 0.301 | -0.5252 | 0.2519 | -- | 61.18 | 577.19 | -861.89 | -- | -- | -- |
| Zealand Pharma A/S | 259.83m | -957.00m | 4.58bn | 345.00 | -- | 5.99 | -- | 17.61 | -22.16 | -23.12 | 6.02 | 16.42 | 0.1297 | 1.99 | 3.89 | 731,901.40 | -47.76 | -31.81 | -57.58 | -37.07 | 62.29 | -- | -368.33 | -247.19 | 4.78 | -- | 0.5268 | -- | -17.19 | 4.85 | -20.24 | -- | 53.47 | -- |
| MorphoSys AG | 1.29bn | -4.43bn | 4.79bn | 652.00 | -- | 4.53 | -- | 3.70 | -17.46 | -17.46 | 5.05 | 4.15 | 0.0847 | 2.04 | 1.98 | 237,552.90 | -29.00 | -13.97 | -32.49 | -15.73 | 79.85 | -- | -342.46 | -89.38 | 4.15 | -3.06 | 0.6984 | -- | -45.19 | 29.28 | -625.55 | -- | 55.11 | -- |
| Alliance Pharma plc | 1.41bn | 63.28m | 5.23bn | 255.00 | 83.36 | 2.14 | 34.74 | 3.71 | 0.0135 | 0.0135 | 0.3024 | 0.5249 | 0.3224 | 2.44 | 6.74 | 640,027.40 | 1.45 | 4.23 | 1.55 | 4.82 | 67.06 | 63.24 | 4.48 | 13.50 | 1.48 | 8.11 | 0.2963 | 39.33 | 25.74 | 10.85 | -8.82 | -16.56 | 31.70 | 6.92 |
| Boiron SA | 3.39bn | 212.51m | 5.27bn | 2.77k | 24.76 | 1.33 | 16.73 | 1.56 | 1.63 | 1.63 | 25.99 | 30.36 | 0.5864 | 1.50 | 4.89 | 164,391.80 | 3.68 | 5.96 | 4.69 | 7.50 | 71.97 | 76.84 | 6.27 | 8.41 | 2.32 | -- | 0.0232 | 46.86 | -11.37 | -5.82 | 8.95 | -18.15 | -10.06 | -9.90 |
| Surgical Science Sweden AB | 339.99m | 70.41m | 5.35bn | 224.00 | 59.52 | 2.09 | 54.27 | 15.74 | 2.54 | 2.54 | 11.73 | 72.32 | 0.1935 | 2.22 | 6.80 | 2,338,335.00 | 4.01 | 3.41 | 4.27 | 3.67 | 69.07 | 78.80 | 20.71 | 15.42 | 2.18 | -- | 0.0432 | 0.00 | 249.98 | 47.90 | 452.66 | 92.43 | 4.25 | -- |
| Eckert&Ziegler Strahlen und Mdzntchnk AG | 1.39bn | 203.41m | 5.80bn | 930.00 | 27.99 | 3.91 | 21.00 | 4.19 | 1.31 | 1.31 | 8.95 | 9.41 | 0.5561 | 2.43 | 5.25 | 214,974.60 | 8.22 | 8.38 | 9.82 | 10.13 | 50.18 | 47.84 | 14.79 | 12.77 | 2.39 | -- | 0.1177 | 35.57 | 2.44 | 5.52 | 62.20 | 27.08 | 40.17 | 24.82 |
| Cosmo Pharmaceuticals NV | 484.11m | 161.23m | 5.94bn | 290.00 | 44.90 | 1.50 | 25.48 | 12.26 | 1.02 | 1.02 | 3.89 | 30.57 | 0.0929 | 3.50 | 2.53 | 226,830.00 | 3.09 | -2.09 | 3.21 | -2.16 | 49.32 | 59.64 | 33.31 | -19.05 | 12.37 | -- | 0.2489 | -- | 6.77 | -0.7776 | 374.29 | 2.30 | -14.33 | -- |
Data as of Jun 24 2022. Currency figures normalised to Zealand Pharma A/S's reporting currency: Danish Krone DKK
30.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Credit Suisse Asset Management (Schweiz) AGas of 31 May 2022 | 2.17m | 4.97% |
| Polar Capital LLPas of 29 Apr 2022 | 2.15m | 4.92% |
| Wellington Management Co. LLPas of 31 Dec 2020 | 1.89m | 4.34% |
| Capital Research & Management Co. (World Investors)as of 23 Feb 2022 | 1.79m | 4.10% |
| T. Rowe Price International Ltd.as of 31 Mar 2022 | 1.38m | 3.16% |
| The Vanguard Group, Inc.as of 02 Jun 2022 | 1.19m | 2.74% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 1.04m | 2.38% |
| Nykredit Bank A/S (Investment Management)as of 29 Apr 2022 | 691.76k | 1.59% |
| BlackRock Fund Advisorsas of 02 Jun 2022 | 505.14k | 1.16% |
| Carmignac Gestion Luxembourg SA (UK)as of 31 Mar 2021 | 484.99k | 1.11% |
More ▼
Data from 31 Dec 2021 - 29 Apr 2022Source: FactSet Research Systems Inc.
